SF Healthcare Week: Capricor CEO Linda Marbán discusses the eventful year the company had for its DMD treatment, Deramiocel, including the P3 HOPE-3 readout, and the regulatory filing and review ahead
- blonca9
- 41 minutes ago
- 1 min read
She describes the HOPE-3 data, the regulatory filing, which has already been initiated in part, and what she believes this treatment means for DMD patients.











.png)

